GlassScriptPhysician profile
Robert J Varipapa
NPI 1063419497
$2,976.74
in general payments reported to CMS, 2019-2025
21 companies · $280 in 2025
The $280 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $17.75 · 2021: $77.41 · 2022: $121 · 2023: $1,723 · 2024: $432 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518 · Travel and Lodging: $916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,518.10 |
| Travel and Lodging | $916.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,380.00 | 2023 | Vns Therapy |
| Abbvie INC. | $421.32 | 2021-2025 | Botox, Ubrelvy |
| Medtronic, INC. | $201.22 | 2023-2024 | Intellis Adaptivestim, Interstim |
| Emd Serono, INC. | $156.80 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $126.09 | 2019-2025 | |
| Lilly USA, LLC | $111.24 | 2023-2024 | |
| Medtronic USA, INC. | $102.26 | 2019 | |
| Penumbra, INC. | $87.31 | 2023 | Artemis |
| Allergan, INC. | $69.87 | 2019-2022 | |
| Biogen, INC. | $54.88 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $48.42 | 2023-2025 | Rytary, Crexont |
| Life Molecular Imaging LTD | $48.22 | 2025 | Neuraceq |
| Celgene Corporation | $27.75 | 2021-2022 | |
| Insightec,INC | $27.49 | 2025 | Exablate |
| Sunovion Pharmaceuticals INC. | $22.09 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $21.94 | 2023 | |
| Genzyme Corporation | $18.38 | 2025 | |
| Acadia Pharmaceuticals INC | $17.11 | 2023 | Nuplazid |
| Idorsia Pharmaceuticals US INC | $15.13 | 2023 | Quviviq |
| Grifols USA, LLC | $12.68 | 2021 | |
| Sumitomo Pharma America, INC. | $6.54 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Varipapa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.